secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001493152-22-000406
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharmaceuticals names Simon Allen CEO effective Feb 1, 2022; Dr. Schneeberger resigns
--------------------------------------------------------------------------------

- Simon Allen appointed CEO and director, effective Feb 1, 2022; succeeds Daniel Schneeberger.
- Dr. Schneeberger's resignation not due to any disagreement with company operations or policies.
- Allen receives $450k base salary; stock options for 625k shares at $6.21 vesting quarterly over 4 years.
- Allen eligible for $1.5M cash bonus if company sold for ≥$500M with Board approval.
- Severance of 9 months base salary plus COBRA reimbursement for 12 months if terminated without cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-000406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer